手术联合化疗及放疗治疗儿童中枢性原始神经外胚瘤的疗效及预后分析

武万水; 刘晶晶; 孙艳玲; 任思其; 邱晓光; 杜淑旭; 李春德; 孙黎明

doi:10.7499/j.issn.1008-8830.1912016

PDF(1596 KB)

HTML

中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (6) : 589-594. DOI: 10.7499/j.issn.1008-8830.1912016

论著·临床研究

手术联合化疗及放疗治疗儿童中枢性原始神经外胚瘤的疗效及预后分析

武万水¹, 刘晶晶¹, 孙艳玲¹, 任思其¹, 邱晓光², 杜淑旭¹, 李春德³, 孙黎明¹

作者信息 +

Clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor and prognostic analysis

WU Wan-Shui¹, LIU Jing-Jing¹, SUN Yan-Ling¹, REN Si-Qi¹, QIU Xiao-Guang², DU Shu-Xu¹, LI Chun-De³, SUN Li-Ming¹

Author information +

文章历史 +

摘要

目的分析手术联合化疗及放疗治疗儿童中枢性原始神经外胚瘤（cPNET）的疗效，并对其预后危险因素进行探讨。方法收集2012年6月至2018年9月诊断为cPNET的42例患儿的临床资料并进行回顾性分析。结果 42例患儿的中位总生存（OS）期为2.0年，中位无事件生存（EFS）期为1.3年；1、3、5年OS率分别为76.2%±6.6%、41.4%±8.7%、37.3%±8.8%，1、3、5年EFS率分别为64.3%±7.4%、32.7%±8.0%、28.0%±8.1%。单因素分析结果显示，不同手术切除方式、化疗次数、危险度分级患儿OS率、EFS率比较差异均有统计学意义（P < 0.05），是否放疗患儿的OS率比较差异亦有统计学意义（P < 0.05）。多因素Cox回归分析结果显示，化疗次数、危险度分级是cPNET患儿OS率及EFS率的独立影响因素（P < 0.05），化疗次数越多，危险度越低，EFS率及OS率越高。结论手术、化疗及放疗联合的综合治疗是目前治疗儿童cPNET的有效方法，早期发现早期治疗及尽量延长、坚持化疗有助于提高EFS率及OS率。

Abstract

Objective To study the clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor (cPNET), as well as the risks factors for poor prognosis. Methods A retrospective analysis was performed for the clinical data of 42 children who were diagnosed with cPNET from June 2012 to September 2018. Results The 42 children had a median overall survival (OS) time of 2.0 years and a median event-free survival (EFS) time of 1.3 years; the 1-, 3-, and 5-year OS rates were 76.2%±6.6%, 41.4%±8.7%, 37.3%±8.8% respectively, and the 1-, 3-, and 5-year EFS rates were 64.3%±7.4%, 32.7%±8.0%, 28.0%±8.1% respectively. The univariate analysis showed that there were significant differences in the OS and EFS rates among the children with different patterns of surgical resection, chemotherapy cycles, and risk grades (P < 0.05), and there was also a significant difference in the OS rate between the children receiving radiotherapy and those not receiving radiotherapy (P < 0.05). The multivariate Cox regression analysis showed that chemotherapy cycles and risk grade were independent influencing factors for EFS and OS rates (P < 0.05). The EFS and OS rates increased with the increase in chemotherapy cycles and the reduction in risk grade. Conclusions Multimodality therapy with surgery, chemotherapy, and radiotherapy is an effective method for the treatment of cPNET in children. Early diagnosis and treatment and adherence to chemotherapy for as long as possible may improve EFS and OS rates.

导出引用

武万水, 刘晶晶, 孙艳玲, 任思其, 邱晓光, 杜淑旭, 李春德, 孙黎明. 手术联合化疗及放疗治疗儿童中枢性原始神经外胚瘤的疗效及预后分析[J]. 中国当代儿科杂志. 2020, 22(6): 589-594 https://doi.org/10.7499/j.issn.1008-8830.1912016

WU Wan-Shui, LIU Jing-Jing, SUN Yan-Ling, REN Si-Qi, QIU Xiao-Guang, DU Shu-Xu, LI Chun-De, SUN Li-Ming. Clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor and prognostic analysis[J]. Chinese Journal of Contemporary Pediatrics. 2020, 22(6): 589-594 https://doi.org/10.7499/j.issn.1008-8830.1912016

参考文献

[1] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2):97-109.
[2] Chintagumpala M, Hassall T, Palmer S, et al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET[J]. Neuro Oncol, 2009, 11(1):33-40.
[3] Gill P, Litzow M, Buckner J, et al. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system[J]. Cancer, 2008, 112(8):1805-1811.
[4] Chang CH, Housepian EM, Herbert JC Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas[J]. Radiology, 1969, 93(6):1351-1359.
[5] Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone[J]. N Engl J Med, 2005, 352(10):978-986.
[6] Sin-Chan P, Li BK, Ho B, et al. Molecular classification and management of rare pediatric embryonal brain tumors[J]. Curr Oncol Rep, 2018, 20(9):69.
[7] Lester RA, Brown LC, Eckel LJ, et al. Clinical outcomes of children and adults with central nervous system primitive neuroectodermal tumor[J]. J Neurooncol, 2014, 120(2):371-379.
[8] Stensvold E, Myklebust TÅ, Cappelen J, et al. Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013:unexplainable regional differences in survival[J]. Pediatr Blood Cancer, 2019, 66(10):e27910.
[9] Kirkman MA, Hayward R, Phipps K, et al. Outcomes in children with central nervous system tumors disseminated at presentation:a large single-center experience[J]. Childs Nerv Syst, 2018, 34(11):2259-2267.
[10] de Rojas T, Bautista F, Flores M, et al. Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain:room for improvement in standards of care[J]. J Neurooncol, 2018, 137(1):205-213.
[11] Gerber NU, von Hoff K, Resch A, et al. Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy[J]. Int J Radiat Oncol Biol Phys, 2014, 89(4):863-871.
[12] Friedrich C, Warmuth-Metz M, von Bueren AO, et al. Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT trials:clinical findings of a rare disease[J]. J Neurosurg Pediatr, 2015, 15(3):227-235.
[13] Timmermann B, Kortmann RD, Kühl J, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children:results of the German HIT-SKK87 and HIT-SKK92 trials[J]. J Clin Oncol, 2006, 24(10):1554-1560.
[14] 沈捷, 袁燕, 胡克, 等. 原始神经外胚层肿瘤预后因素分析[J]. 中华肿瘤杂志, 2018, 40(8):614-618.
[15] Garcia-Moure M, Martinez-Velez N, Gonzalez-Huarriz M, et al. The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models[J]. Sci Rep, 2019, 9(1):14368.
[16] Carceller F, Bautista F, Jiménez I, et al. Outcome of children and adolescents with central nervous system tumors in phase I trials[J]. J Neurooncol, 2018, 137(1):83-92.
[17] Carceller F, Bautista FJ, Jiménez I, et al. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe:an innovative therapies for children with cancer study[J]. Eur J Cancer, 2016, 67:130-140.
[18] Ma J, Ma S, Yang J, et al. Primary spinal primitive neuroectodermal tumor:a single center series with literature review[J]. J Spinal Cord Med, 2018. DOI:10.1080/10790268.2018.1547862. Online ahead of print.